[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-healing-wound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-healing-wound":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,76,113,137,157,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100116157","mechanisms-underlying-impaired-diabetic-wound-healing-100116157",false,"NCT00777712","Mechanisms Underlying Impaired Diabetic Wound Healing","Mechanisms Underlying Impaired Wound Healing","WoundVAC","Inclusion Criteria:\n\n* Ages 21-80\n* Chronic Wound (present \\>4 weeks)\n* Diabetic \\& Non-diabetic\n* Adult surgical wounds\n\nExclusion Criteria:\n\n* Inability to consent\n* Pregnant women\n* Therapeutically immunocompromised\n* Individuals defined in 45 CFR 46 Subparts B,C, and D, nor from any other population considered vulnerable 2.9","ALL","21 Years","80 Years",{"count":21,"type":22},250,"ESTIMATED","OBSERVATIONAL","The overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals with diabetes. Biology of normal (peripheral blood derived cells) versus wound derived cells will also be studied.",[26],"Non-healing Wound",[28,29,30,31,32,33],"Wound healing","diabetes","inflammatory cell","monocyte","leukocyte","macrophage","RECRUITING","2026-06-03",{"date":37,"type":38},"2026-06-05","ACTUAL",{"date":40,"type":38},"2008-09-01",{"date":42,"type":22},"2030-12-31",{"name":44,"class":45},"University of Pittsburgh","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100541227","phase-2-antibiotic-tumescent-for-chronic-wounds-100541227","NCT06327113","Antibiotic Tumescent For Chronic Wounds","A Phase 2 Randomized Study Comparing Subcutaneous Tumescent Antibiotic Administration With Standard of Care for the Treatment of Chronic Wounds","TAI","Inclusion Criteria:\n\n* Male or female ≥18 years of age.\n* Must have:\n\n  1. One or more full thickness ulcers on the lower extremity, upper extremity (excluding the hands) or trunk with a surface area exceeding 0.5 cm\\^2 (50 mm\\^2) and less than 30 cm\\^2 (6\\*5 cm) after debridement (full thickness means extending through the epidermis and dermis but not involving tendon, bone or joint capsule).\n  2. Presence of a chronic wound (including venous ulcer, arterial ulcer, below knee pressure ulcer, diabetic foot ulcer, ischemic ulcer) that has existed for \\>4 weeks at Visit 1.\n  3. Documentation that the wound has been treated at least 2 times at the wound care center.\n  4. Documentation that the wound area has not decreased by more than 50% in 4 weeks.\n  5. Willing to provide written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study.\n* Adequate perfusion as demonstrated by TcPO2≥40 mm Hg, ABI ≥ 0.7, or great toe pressure≥50 mm Hg, or palpable pulses of the lower extremity such as dorsalis pedis and\u002For posterior tibial artery or palpable radial artery in the upper extremity.\n* In the opinion of the investigator, participants must be considered reliable, willing, and able to give signed informed consent in English and sign the informed consent form.\n* For participants of reproductive potential, two of the following forms of contraception are required between visits 1-4 (total of 3-6 weeks), one of which must be a barrier method:\n\n  1. Condoms (male or female) with or without a spermicidal agent\n  2. Diaphragm or cervical cap with spermicide\n  3. Intrauterine device (IUD)\n  4. Tubal ligation\n  5. Hormone-based contraceptive such as oral birth control pills\n\nExclusion Criteria:\n\n* Participants with limb threatening infection, extensive cellulitis (≥2 cm radially beyond the borders of the wound), lymphangitis, fasciitis, deep tissue infection, abscess, pus, osteomyelitis, or other evidence of local or systemic complications of infection.\n\n  1. Wound size\u002Fsurface area, duration, severity, or location outside of INCLUSION criteria Note: Consideration will be given to minor variation, if deemed appropriate by the medical director, and authorized.\n  2. Clinically severe wound at high risk for amputation as determined by the Medical Director.\n  3. All pressure ulcers except below knee pressure ulcers.\n* Cellulitis or acute infection as determined by:\n\n  1. Significant wound erythema, induration, warmth, presence of pus, or tenderness, determined by PI or medical director ≥ 2 cm radially from wound margin.\n  2. Fever with electronic temp \\>100.4°F (\\>38°C)\n* Following enrollment, if wound culture returns positive for Pseudomonas.\n* Participants with symptoms of systemic infection or uncontrolled diabetes mellitus (e.g., severe hyperglycemia, ketoacidosis, azotemia).\n* Participants who are allergic or have shown hypersensitivity to penicillin, cefazolin, other beta-lactams, the cephalosporin group of antibiotics, lidocaine, or to local anesthetics of the amide type.\n* Participants requiring intravenous antimicrobials during the study period for any infection, including diabetic foot ulcer. Mild localized infection that would be treated on an outpatient basis could be approved by Medical Director authorization.\n* Participants who are currently treated by dialysis, awaiting dialysis, or who have an estimated glomerular filtration rate of ≤ 30 mL\u002Fmin\u002F1.73 m\\^2.\n* Participants who are expected to be unable to care for their ulcer because of hospitalization, vacation, disability, etc., during the study period.\n* Participants with known active alcohol or substance abuse within the 6 months preceding study entry.\n* Participants who are receiving systemic corticosteroids (in a dose equivalent to ≥20 mg of prednisone per day), biologic therapy, immunosuppressants, , radiation therapy, or cytotoxic agents, unless approved by medical director authorization\n* Participants who require treatment for a primary or metastatic malignancy (other than squamous or basal cell carcinoma of the skin, not involving the wound site).\n* Participants with acquired immune deficiency syndrome (AIDS) or known human immunodeficiency virus (HIV) positivity.\n* Participants with other conditions considered by the investigator to be reasons for disqualification that may jeopardize participant safety or interfere with the objectives of the trial (e.g., acute illness or exacerbation of chronic illness, lack of motivation, history of poor compliance).\n* Women who are breastfeeding, pregnant, or attempting to become pregnant.\n* Active acute medically unstable condition defined by:\n\n  1. Diabetes Mellitus Type 1 or 2, with A1C greater than 9.5. Consideration to HbA1c higher than 9.5 - 10.0% after consultation with the medical director or PI.\n  2. Unstable cardiovascular or other high-risk general medical condition making participation in the study a significant risk to the participant, per medical director determination.\n  3. Laboratory evidence of severe metabolic, renal, hepatic, endocrine, hematologic disorder per medical director determination.\n  4. Recent trauma complicated by significant bone, nerve, or vascular damage.\n  5. Sickle Cell Disease.\n* Participant is enrolled\u002Fparticipating in another study or does not agree to refrain from participating in another study while enrolled in this study.","18 Years",{"count":57,"type":22},60,"INTERVENTIONAL",[60],"PHASE2","Chronic non-healing wounds are becoming an increasingly more common problem. Eligible, consenting patients with chronic wounds in the lower extremities, upper extremities or trunk, will either continue to the standard of care or will be randomized to the treatment cohort where antibiotic solution will be injected in the area around the wound. All patients will continue standard wound care as dictated by the wound care clinic. Subjects of both the control and treatment will have approximately 6 study specific visits that may or may not coincide with previously schedule wound care clinic visits. As these specified visits wound size and healing will be documented and patients will complete surveys. The study will conclude for the subject after approximately 6 months. Again, these patients may continue standard wound care but will no longer have study obligations.",[26],[64,65],"chronic wound","wound care","2026-04-21",{"date":68,"type":38},"2026-04-23",{"date":70,"type":38},"2024-05-17",{"date":72,"type":22},"2028-05-25",{"name":74,"class":45},"University of California, Los Angeles",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":88,"conditions":89,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100570426","phase-3-tissue-repair-gel-in-venous-leg-ulcers-us-100570426","NCT06707090","Tissue Repair Gel in Venous Leg Ulcers (US)","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* Participants considered nutritionally deficient.",{"count":85,"type":22},312,[87],"PHASE3","The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[90,91,92,93,94,95,96,26],"Venous Leg Ulcer","Venous Ulcer","Venous Stasis Ulcer","Venous Stasis","Wound Heal","Wounds","Venous Insufficiency of Leg",[98,99,100,101,102],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2026-02-09",{"date":105,"type":38},"2026-02-12",{"date":107,"type":38},"2025-01-28",{"date":109,"type":22},"2028-02",{"name":100,"class":111},"INDUSTRY",33,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":58,"phases":122,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":75},"100496049","a-study-to-evaluate-microvessel-ultrasound-imaging-of-wound-healing-in-patients-with-chronic-ulcers-100496049","NCT05739149","A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers","Microvessel Ultrasound Imaging of the Skin and Subcutaneous Tissues to Evaluate Wound Healing in Patients With Chronic Ulcers","Inclusion Criteria:\n\n* Chronic wound in the course of diabetic foot ulcers and\u002For lower extremity venous ulcers with duration of at least 6 weeks and the wound surface not less than 2 sq. cm and not greater than 15 sq. cm, without evidence of active infection of the wound at the time of qualification to participate in the study\n* Meets criteria for stalled chronic wound defined as less than 50% reduction in wound size after 30 days of standard of care management.\n* For chronic venous ulcers, ultrasound demonstrates venous reflux \\>0.5 seconds\n* Satisfactory blood glucose control - fasting not more than 110 mg%, HbA1c \\\u003C6.5%\n* Satisfactory blood supply to the wound verified by the measurement of the oxygen level of the foot tissue (TCPO2 \\> 30mmHg) in patients with neuropathic etiology of diabetic foot syndrome\n* In the case of the patients with the wounds of ischemic component, the condition for qualification is a clinical improvement of the limb's blood supply as a result of the revascularization procedure documented by ultrasound.\n* Ankle-brachial index (ABI) ≥ 0.8\n\nExclusion Criteria:\n\n* Acute wound with duration less than 6 weeks\n* Evidence of active infection or on antibiotics\n* Smoker\n* For chronic venous ulcers, ultrasound demonstrates venous reflux \\\u003C0.5 seconds\n* Unsatisfactory blood glucose control - fasting more than 110 mg%, HbA1c \\\u003C6.5%\n* Poor blood supply to the wound verified by the measurement of the oxygen level of the foot tissue (TCPO2 \\\u003C 30mmHg) in patients with neuropathic etiology of diabetic foot syndrome\n* Ankle-brachial index (ABI) \\\u003C 0.\n* Pregnancy\n* Known allergy to lidocaine",{"count":121,"type":22},10,[123],"NA","The purpose of this research is to explore the use of high-resolution microvessel ultrasound imaging system to look for scarring and to monitor wound healing and to see if treatment affects the amount of tiny vessels and circulation around the wound.",[126,26,127],"Non-Healing Ulcer of Skin","Lower Extremity Wound","2026-01-20",{"date":130,"type":38},"2026-01-22",{"date":132,"type":38},"2023-12-01",{"date":134,"type":22},"2026-12-10",{"name":136,"class":45},"Mayo Clinic",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":81,"acronym":82,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":58,"phases":144,"briefSummary":88,"conditions":145,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100570427","phase-3-tissue-repair-gel-in-venous-leg-ulcers-in-auus-100570427","NCT06707103","Tissue Repair Gel in Venous Leg Ulcers in AU\u002FUS","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* History of cancer in the preceding 5 years (except as noted in the protocol).\n* Participants considered nutritionally deficient.",{"count":85,"type":22},[87],[90,91,92,93,94,146,96,26],"Wound",[98,99,100,101,102],"2025-03-27",{"date":150,"type":38},"2025-04-02",{"date":152,"type":22},"2025-04",{"date":154,"type":22},"2027-02",{"name":100,"class":111},12,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":167,"conditions":168,"keywords":176,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":75},"100574372","hierarchy-of-effects-of-laboratory-markers-and-their-interaction-with-comorbidity-concerning-outcome-and-personalized-treatment-of-trauma-patients-in-emergency-care-and-rehabilitation-100574372","NCT06758427","Hierarchy of Effects of Laboratory Markers and Their Interaction With Comorbidity Concerning Outcome and Personalized Treatment of Trauma Patients in Emergency Care and Rehabilitation","HELICOPTER","Inclusion Criteria:\n\n* acute long bone fracture (humerus, ulna, radius, femur, tibia) with surgical treatment\n\nExclusion Criteria:\n\n* associated severe injury (ISS \\> 16)\n* associated traumatic brain injury\n* associated traumatic spine injury\n* dementia","67 Years",{"count":166,"type":22},2300,"At least ten percent of trauma patients suffer from any sort of complication. The study aims to identify a risk factor profile to early identify trauma patients at risk.",[169,170,171,26,172,173,174,175],"Postoperative Complications","Surgical Site Infection","Wound Infection","Pseudarthrosis","Bone Infection","Pneumonia","Nosocomial Infection",[177],"long bone fracture, trauma","NOT_YET_RECRUITING","2024-12-27",{"date":181,"type":38},"2025-01-03",{"date":183,"type":22},"2025-02-01",{"date":185,"type":22},"2027-10-31",{"name":187,"class":45},"Department of Trauma and Reconstructive Surgery at Eberhard Karls University Tuebingen, BG Klinik Tu",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":195,"targetDuration":4,"studyType":58,"phases":197,"briefSummary":198,"conditions":199,"keywords":207,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":75},"100458581","examining-the-effectiveness-of-dermgen-in-the-treatment-of-diabetic-foot-ulcers-in-first-nations-people-100458581","NCT05251480","Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People","Examining the Effectiveness of DermGEN™ Versus Standard of Care in the Treatment of Diabetic Foot Ulcers in First Nations People Living in Northwestern Ontario Communities","Inclusion Criteria:\n\n* Participant and social support (e.g., family, caregiver) ready and willing to participate and comply with follow-up regime\n* Participant willing to be involved in self-care (e.g., keep dressing dry at home) required during treatment\n* Participant willing to wear Total Contact Cast (TCC) for wound off-loading during treatment\n* Participant or legal representative has read and signed the informed consent form\n* Documented stable Type I or II diabetes (HbA1C between 5.0 to 10 mmol\u002FL within 1 month prior to Day 0)\n* Ulcer has been present for a minimum of 2 weeks as of Day 0\n* Ulcer area is ≥2 cm2 prior to debridement at Day 0 of study\n* Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule\n* Ulcer is free of dead tissue and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting on Day 0\n* Adequate perfusion to the extremity determined by at least one of the following:\n\nPalpable pedal pulses, Transcutaneous oxygen measurement at the dorsum of the foot ≥30 mm Hg, Ankle-brachial index ranging from 0.8 to 1.2, At least biphasic Doppler arterial waveforms at the dorsalis pedis and posterior tibial arteries\n\nExclusion Criteria:\n\n* The individual has any condition that seriously compromises their capacity to provide consent and answers questions related to this study.\n* Untreated infection of soft tissue or bone and\u002For autoimmune connective tissue disorders\n* Ulcer is over Charcot deformity (joints deformity of foot and ankle common in people with diabetes)\n* Body mass index ≥50 kg\u002Fm2\n* Ulcer is not classified as diabetes-related\n* Ulcer has tunnels or sinus tracts that cannot be completely debrided\n* Medical condition(s) that in the investigators' opinion make the patient inappropriate for study (e.g active liver disease)\n* Presence of malignant disease not in remission for 5 years or more\n* The individual is undergoing chemotherapy\u002Fradiation therapy\n* The individual received radiation therapy within 30 days of Day 0 of study\n* The individual is taking an immunosuppressant medication (e.g., corticosteroids, immunosuppression or cytotoxic agents), or is anticipated to require such agents during study\n* Presence of acute or chronic hepatitis, liver disease, anemia, serum albumin \\\u003C2.0 gm\u002FdL, or has alkaline phosphatase or LDH at twice the normal upper limit\n* Obvious clinical signs and symptoms of ongoing tissue infection (i.e., cellulitis) or bone infection (i.e., osteomyelitis)\n* Female individuals are pregnant at time or intend to get pregnant during study time\n* The individual has known allergies to antibiotics, such as penicillin and streptomycin\n* The individual is an active smoker (smoke one or more cigarette a day)\n* The individual has a history of a bleeding disorder or is taking blood thinner medication",{"count":196,"type":22},120,[123],"The study will examine the effectiveness of a decellularized dermal matrix (i.e., DermGEN™) in improving wound healing, quality of life and associated costs of treatment of DFUs in First Nations people living in the Northwestern Ontario Communities. First Nations people with active diabetic foot (DFU) ulcer attending a wound care clinic located at the Rainy River district office. An interventional, two-arm, randomized, prospective study of (1) standard of care (control) vs. (2) DermGEN™ - a decellularized dermal matrix (treatment) will be used in the treatment and management of DFU. Patients will be randomized to each arm (n=60 per arm) based on power calculations using data from our Pilot study.",[200,201,202,203,26,204,205,206],"Diabetes Mellitus","Ulcer Foot","Ulcer Healing","Diabetic Foot Ulcer","Wound of Skin","Wound; Foot","Tissue Injury",[208,203,26,209,210,211,212,213,214,215],"Diabetic Ulcer","Tissue Engineering","Regenerative Medicine","Decellularized Matrix","Acellular Dermal Matrix","Tissue Allograft","Indigenous Healing","Advanced Wound Care","2024-07-02",{"date":218,"type":38},"2024-07-03",{"date":220,"type":22},"2024-12-30",{"date":222,"type":22},"2026-12-01",{"name":224,"class":111},"DeCell Technologies Inc."]